Access Pharmaceuticals, Reduce Glucose Levels in Pre-clinical Testing of Cobalamin Oral Insulin

Dec. 7 , 2007 - Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced that it has demonstrated the ability, using the company's proprietary Cobalamin(TM) technology, to significantly reduce glucose levels in an animal model of diabetes, through its oral insulin product candidate. Several formulations using Cobalamin, which is based upon the body's natural absorption of vitamin B12 in the gastrointestinal tract, were tested in an animal model of diabetes. Additional pre-clinical studies are planned... [PDF] Access Pharmaceuticals' Press Release -

Keryx , Sulodexide Phase 3 study to continue without modification

Dec. 5, 2007 - Keryx Biopharmaceuticals (Nasdaq: KERX) announced that the Independent Data Safety Monitoring Committee (DSMC) responsible for monitoring Sulonex(TM) (sulodexide oral gelcaps), the Company's lead drug candidate under development as a treatment for diabetic nephropathy , recently met to evaluate the data from the ongoing Phase 3 trial... Keryx Biopharmaceuticals' Press Release -

Targacept , TC-6499, Neuropathic Pain Candidate

December 10, 2007 - Targacept, Inc. (Nasdaq: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), announced that it has initiated a Phase I clinical trial of its product candidate TC-6499. The initiation of the trial triggers a $6.0 million milestone payment to Targacept under the terms of its alliance agreement with GlaxoSmithKline...Neuropathic pain is characterized as severe, stabbing, burning or tingling and is most often associated with diabetes mellitus... Targacept's Press Release -

Trinity Biotech, FDA Clearance of TRIstat Point-of-Care HbA1c Test

November 29th, 2007 - Trinity Biotech plc (NASDAQ: TRIB) a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced that the US Food and Drug Administration has given clearance to market the rapid, point-of-care TRIstat™ HbA1c system... [PDF] Trinity Biotech's Press Release -

Phase IIb Trial of EpiCept NP-1 in Diabetic Peripheral Neuropathy

Dec 03, 2007 - EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced that it has completed patient enrollment in the Phase IIb "Neuracept" trial for EpiCept(TM) NP-1 cream. EpiCept NP-1 is a patented topical cream formulation of two FDA- approved drugs, 4% amitriptyline and 2% ketamine, and is intended to provide long-term relief from the pain of peripheral neuropathies... EpiCept 's Press Release -

Regenetech , Preclinical Studies at Johns Hopkins University with Expanded Adult Stem Cells for Type 1 Diabetes Treatment

14 November 2007 - Regenetech, Inc. announces that it has signed a Sponsored Research Agreement (SRA) with Johns Hopkins University in order to work toward a treatment for type 1 diabetes. This is in addition to the research agreements which the Company currently has in place with Texas A&M University and the University of Texas Medical Branch at Galveston. Regenetech is pioneering the development and commercialization of technology which the company believes will enable regenerative therapy with adult stem cells for widespread use... Regenetech's Press Release -

Cardium, Phase 2b Excellarate Clinical Study for Diabetic Ulcers

Nov. 14, 2007--Cardium Therapeutics (AMEX:CXM) and its subsidiary, Tissue Repair Company (TRC) announced the start of recruitment for its Phase 2b clinical trial (MATRIX) to evaluate the safety and efficacy of Excellarate(TM) for the potential treatment of non-healing diabetic foot ulcers. Excellarate is a DNA-based topical gel that is being developed to be administered once or twice to stimulate wound healing... Cardium's Press Release -

DexCom, FDA Approval to Calibrate Its SEVEN Continuous Glucose Monitoring System Using Any FDA Cleared Blood Glucose Meter

November 16, 2007 - DexCom, Inc. (NASDAQ: DXCM) announced that it has received Food and Drug Administration (FDA) approval to calibrate the SEVEN^TM, its seven-day continuous glucose monitoring system, using any FDA cleared blood glucose meter. With this approval, patients will be able to calibrate the system without using a connection cable. DexCom expects to launch this feature to new patients near the end of the first quarter of 2008 and upgrade existing patients during the second quarter of 2008... DexCom's Press Release -

DIAMYD, A TYPE 1 DIABETES TRIAL WITH THE EXPERIMENTAL DIAMYD DIABETES VACCINE

November 22, 2007 - Diamyd Medical announced that it has executed a Clinical Trial Agreement with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for a planned clinical study with the Diamyd® GAD-alum diabetes vaccine in 126 new onset type 1 diabetes patients. The clinical study will be conducted by the NIDDK-sponsored consortium Type 1 Diabetes TrialNet. Under the terms of the agreement, Diamyd Medical will supply clinical-grade material (i.e. Diamyd® and placebo) for the trial... Diamyd's Press Release -

JDRF and Lilly, Research to Identify Beta Cell Biomarkers

Nov 14, 2007 - The Juvenile Diabetes Research Foundation and Eli Lilly and Company announced today that they are joining together to create a $3 million research effort to accelerate the pace of research into drugs and therapies to cure diabetes and its complications by developing biomarkers -- indicators that can measure the progress of disease and the effectiveness of therapeutics... Lilly's Press Release -

Osiris Therapeutics, Phase II Clinical Trial Evaluating Prochymal(TM) for Type 1 Diabetes

Oct 25, 2007 - "Prochymal has shown promise in Phase II clinical trials as a therapy for severe immune mediated conditions including Crohn's Disease and GVHD, and as a result has advanced into Phase III pivotal trials," said C. Randal Mills, Ph.D., President and CEO of Osiris Therapeutics. "It is appropriate to evaluate related conditions such as type 1 diabetes, where data indicates Prochymal may also be of therapeutic benefit. We are honored that JDRF has selected Prochymal as a promising new therapy for evaluation."... Osiris Therapeutics' Press Release -

CV Therapeutics' Anti-Ischemic Agent Ranexa(R), Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36

Nov. 6, 2007- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that data from a prospectively identified analysis of 2,220 diabetic patients from the MERLIN TIMI-36 study showed that Ranexa(R) (ranolazine extended-release tablets) significantly reduced hemoglobin A1c (HbA1c), increased the number of patients achieving the clinical HbA1c treatment target of 7.0 percent or less and reduced the incidence of newly increased HbA1c in patients without diabetes at baseline... CV Therapeutics' Press Release -

Sangamo BioSciences, ZFP Therapeutic Data From Nerve Regeneration Program

Nov 07, 2007 -...We believe that these effects will prove therapeutically important in conditions that involve nerve damage including diabetic neuropathy, ALS, stroke and traumatic injuries to the brain, spinal cord and other nerves. We are very pleased to collaborate with Dr. Michael Fehlings, senior author of this study, who is world-renown for his work on SCI and has significant clinical trial experience in this area."... Sangamo 's Press Release -

Sirtris, Novel Endogenous SIRT1 Activator

Nov. 9, 2007--... The natural SIRT1 activator, AROS, and Sirtris' proprietary SIRT1 activators both bind to the N-terminus of SIRT1. This further validates SRT501, and more potent Sirtris new chemical entities that are up to 1000 times more potent than SRT501, as potential drug targets for diseases of aging including metabolic disorders such as Type 2 Diabetes, mitochondrial disorders such as MELAS, neurological disorders, and cancer.... Sirtris Press Release -

Forbes Medi-Tech, Final Steps in Compound Selection for Type 2 Diabetes

Tue Oct 30, 2007 - Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) announced that it has entered the final stages of compound selection for two of the most rapidly growing therapeutic indications, asthma and type 2 diabetes... Forbes Medi-Tech's Press Release -

Nanomix, Exclusive Glucose Detection Licensing Agreement with MysticMD

November 5, 2007 - Nanomix Inc., a leading electronic detection company commercializing high-value diagnostic and monitoring applications, today announced an exclusive licensing agreement with MysticMD Inc., a provider of proprietary nano-coatings. Per this agreement, MysticMD will provide Nanomix with intellectual property related to the use of nano-ink for glucose test strip technology... Nanomix's Press Release [PDF] -

SemBioSys, insulin data

Oct. 26, 2007 - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, announced that it will be presenting a scientific poster and abstract at the Seventh Annual Diabetes Technology Meeting in San Francisco hosted by the Diabetes Technology Society. The poster will disclose SemBioSys' recent accomplishments in the development of a highly-scalable, low-cost source of recombinant human insulin... SemBioSys' Press Release -

Synvista's Alagebrium, Potential for use in Treating Diabetes-Related Gastrointestinal Complications

Oct. 25 , 2007 - Synvista Therapeutics, Inc. (AMEX: SYI) announced the publication of preclinical data demonstrating the ability of its compound, alagebrium, to reduce serum levels of advanced glycated end-products (AGEs) and restore neuronal nitric oxide synthase (nNOS) activity in rats with diabetes... Synvista's Press Release -

Isis, New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes

Oct 18, 2007 - Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that it has added a new diabetes drug targeting the sodium dependent glucose transporter type 2 (SGLT2) to its development pipeline. ISIS 388626, a generation 2.2 antisense drug that acts in the kidney to increase glucose excretion, complements Isis' existing pipeline of drugs in development for the treatment of diabetes, each of which act upon targets in the liver through distinct mechanisms to improve insulin sensitivity, reduce glucose production*, or affect other metabolic aspects of this complex disease... Isis' Press Release -

Lilly and MacroGenics, Licensing and Collaboration Agreement

10/18/2007 – Eli Lilly and Company (NYSE:LLY) and MacroGenics, Inc. announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases. As part of the deal, Lilly will acquire the exclusive rights to the molecule. Teplizumab is currently being studied in the PROTÉGÉ trial, a global pivotal Phase II/III clinical trial for individuals with recent-onset type 1 diabetes*... MacroGenics' Press Release - Lilly's Press Release -

Flamel Technologies, Positive Results of a Phase I Trial

October 18, 2007 - Flamel Technologies (NASDAQ:FLML) announced positive preliminary Phase I data from a trial comparing the safety, tolerability, and long-acting activity of FT-105 versus Lantus , an approved basal insulin. FT-105 is a long-acting recombinant insulin formulation that uses a new microparticulate adaptation of Flamel's proprietary Medusa® nanoparticle delivery system... Flamel Technologies' Press Release -

Generex Biotechnology, Contract Research Organization to Manage Global Phase III Trials For Generex Oral-lyn

Oct. 16, 2007 - Generex Biotechnology Corporation (NasdaqCM:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced that it has entered into a number of key service agreements for its global Phase III trials for Generex Oral-lyn, its proprietary oral insulin spray product... Generex Biotechnology's Press Release -

DARA BioSciences and Bayer Pharmaceuticals, Exclusive License Agreement

October 17, 2007 - DARA BioSciences, Inc. and Bayer Pharmaceuticals Corporation (BPC), a U.S. subsidiary of Bayer HealthCare AG signed a license agreement granting DARA BioSciences exclusive worldwide rights to a series of patents and compounds for the treatment of metabolic diseases, in particular type 2 diabetes and dyslipidemia. Lead compounds are in later preclinical development... DARA BioSciences' Press Release -

Merck , Supplemental New Drug Applications for JANUVIA

Oct. 17, 2007 - Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for JANUVIA™ (sitagliptin), the only DPP-4 inhibitor available in the United States for the treatment of type 2 diabetes. JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. JANUVIA has not been studied in combination with insulin.... Merck's Press Release -

Johnson & Johnson, Global Diabetes Institute

October 16, 2007– Johnson & Johnson (NYSE: JNJ) announced the establishment of the Johnson & Johnson Diabetes Institute (JJDI) to transform diabetes care by providing comprehensive training on the latest practice standards, new diabetes tools and technologies and reimbursement solutions to physicians, nurses, physician assistants and diabetes educators around the globe... Johnson & Johnson's Press Release -

Exelixis, Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy

Oct. 16, 2007 - Exelixis, Inc. (Nasdaq: EXEL) announced that a recently completed phase 2 trial of XL784 did not meet its primary endpoint of reducing proteinuria compared with placebo in patients with proteinuria associated with diabetic nephropathy... Exelixis' Press Release -

Hollis-Eden Pharmaceuticals, Phase I/II Clinical Trial with TRIOLEX(TM) (HE3286) in Obese, Insulin Resistant Volunteers

Oct. 16, 2007--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, announced that it is commencing this week a two-stage Phase I/II clinical trial with its oral drug candidate TRIOLEX(TM) (HE3286) in obese, insulin resistant volunteers. TRIOLEX represents a novel class of insulin sensitizers that the Company believes acts by modulating the anti-inflammatory pathway NF-kappaB... Hollis-Eden Pharmaceuticals' Press Release -

Living Cell Technologies, Positive Preliminary Data From DiabeCell® Phase I/IIa Trial in Type I Diabetes

October 9, 2007 - Living Cell Technologies Limited (ASX: LCT) released positive preliminary results for its Phase I/IIa clinical trial of the company's proprietary DiabeCell® porcine for the treatment of type 1 diabetes. The clinical trial is being conducted in six type 1 (insulin-dependent) diabetic patients... Living Cell Technologies' Press Release -

Isis, $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007

Calif., Oct 09, 2007 - Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that it has received a $1.25 million milestone payment in the form of equity securities in iCo Therapeutics. The milestone was related to the initiation of Phase 1 clinical trials of iCo-007, a drug licensed to iCo by Isis in 2005 for the treatment of various eye diseases, including diabetic macular edema...
Isis' Press Release - iCo's Press Release -

Johnson & Johnson Pharmaceutical R & D, Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections

October 8, 2007 – Johnson & Johnson Pharmaceutical Research & Development, L.L.C., announced results from a Phase III trial that showed that investigational antibiotic ceftobiprole was found to clinically cure 86% of patients with diabetic foot infections -- including some infections that were caused by methicillin-resistant Staphylococcus aureus (MRSA)... Johnson & Johnson's Press Release -

Akesis Pharmaceuticals , IND for Phase IIa Trial of AKP-020 to Treat Type 2 Diabetes

Oct 8, 2007 - - Akesis Pharmaceuticals, Inc. (OTC/BB: AKES), an emerging diabetes drug-development company, announced that it has filed its first Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its lead product candidate AKP-020, a novel vanadium compound that is expected to show considerable potential as a treatment for patients with Type 2 Diabetes... Akesis' Press Release -

Alimera Sciences and pSivida , Pivotal Phase 3 Trial of Medidur™ FA for Diabetic Macular Edema

October 08, 2007 - Alimera Sciences Inc., a privately held ophthalmic pharmaceutical company, and pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI), announced that enrollment is complete for the FAME™ (Fluocinolone Acetonide in Diabetic Macular Edema) Study of Medidur™ FA for the treatment of Diabetic Macular Edema...
Alimera Sciences' Press Release - pSivida's Press release -

MyCareTeam, New Diabetes Tool Available on ADA Web Site

October 4, 2007– The American Diabetes Association unveiled a new web-based diabetes tool that makes it easier for people with diabetes – and their care providers – to share and organize important health information to improve their diabetes care. The tool, My Diabetes Connector, is a diabetes management software application developed by
a software and services company, MyCareTeam, Inc...
ADA's Press Realease on MyCareTeam [PDF] -

VERICHIP and DIGITAL ANGEL, IMPLANTABLE RFID GLUCOSE-SENSING MICROCHIP

September 24, 2007 - VeriChip Corporation (NASDAQ:CHIP), a provider of RFID systems for healthcare and patient-related needs, and Digital Angel Corporation (AMEX: DOC), owner of Patent No. 7,125,382 for an embedded bio-sensor system, announced they have entered into a memorandum of understanding with RECEPTORS LLC, an expert in the field of proteomics and the development of artificial receptors to develop a prototype renewable glucose sensor to use in conjunction with an implantable bio-sensing RFID microchip to measure glucose levels in the human body. VeriChip will manage the partnership project, with the assistance of Digital Angel, aimed at accelerating the development of an embedded glucose bio-sensing system for humans. RECEPTORS will be responsible for demonstrating a self-contained glucose-sensing system in Phase I of the project...
VeriChip's Press Release - Digital Angel's press Release - RECEPTORS' Press release [PDF] -

HMM , Blood Glucose Meter for Self-Monitoring With Bluetooth Technology

the First CE-Certified and EU-Registered Blood Glucose Meter for Self-Monitoring With Bluetooth Technology on the Market :

October 4, 2007 - HMM Heidelberger-Medical-Marketing GmbH - Always One Step Ahead.
"Finally - our smartLABgenie is available on the market. Initiator of this product introduction was the desire of many patients for a compact, easy-to-use and at the same time modern tool to smoothly and easily control every day influences on diabetics. The huge advantage: The Bluetooth option renders it possible to integrate our smartLABgenie in every telemedicine system, as well as to transfer data via cell phone and PC..."... HMM's Press Release -

Home Diagnostics on Microsoft HealthVault

Thursday October 4, 2007 - Home Diagnostics, Inc. (Nasdaq:HDIX), a leading manufacturer and marketer of diabetes testing supplies, announced its TRUEtrack® and TRUEread™ blood glucose meters will operate on Microsoft HealthVault, a newly launched consumer health platform. The integrated system will enable TRUEtrack and TRUEread users to download data directly from the meter to the online platform, providing the ability to collect, organize and share diabetes management information in a privacy- and security-enhanced setting... Home Diagnostics' Press Release -

Phylonix Phase II SBIR to Develop Zebrafish Models for Eye Diseases

October 2, 2007- Phylonix Pharmaceuticals, Inc. announced that it has been awarded a $1,092,031 Phase II Small Business Innovation Grant (SBIR) from the National Eye Institute of the National Institutes of Health (NIH) to develop zebrafish eye disease models for drug screening. The grant for "New Models for Eye Diseases" will support the Phylonix program over a period of three years... Phylonix is modeling a number of eye diseases in zebrafish including diabetic retinopathy and AMD, the two leading causes of blindness in adults in the industrialized world... Phylonix Pharmaceuticals' Press Release -

CardioVascular BioTherapeutics, Phase I Wound Healing Trial

Oct. 2, 2007--CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT) today announced the completion of its Phase I wound healing clinical trial aimed at evaluating the safety and tolerability of the company's protein-based drug candidate (CVBT-141B), formulated with human fibroblast growth factor -1 (FGF-1), in patients suffering from either diabetic or venous stasis ulcers. FGF-1 was applied topically in 8 subjects at a single site and was found to be well tolerated... CardioVascular BioTherapeutics' Press Release -

Generex Biotechnology, new United States Patent

Mass., Oct. 2, 2007 - Generex Biotechnology Corporation (NasdaqCM:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced that the United States Patent and Trademark Office has granted the Company a new United States Patent.
The patent, titled ``Metered Dose Spray Device for Use with Macromolecular Pharmaceutical Agents such as Insulin,''... Generex Biotechnology's Press Release -

DiaMedica, phase II results for DM-71 in type 2 diabetes trial

October 1, 2007 - DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for type 2 diabetes, is pleased to announce exciting results for DM-71 in its proof-of-concept phase II clinical study in type 2 diabetes... DiaMedica's Press Release -

Novartis, Galvus European approval as new treatment for type 2 diabetes

September 28, 2007 - Galvus (vildagliptin), a new once-daily oral treatment for patients with type 2 diabetes, has been granted European Union approval. Galvus is the only drug in its class to offer such a broad range of indications for use in combination therapies with other anti-diabetic medicines... Novartis' Press Release -

GlucoLight, Patent for Sentris-100™ Blood Glucose Monitoring Technology

September 26, 2007 - GlucoLight Corporation, a development-stage company focused on blood glucose monitoring in the acute care environment, announced that it has been awarded U.S. Patent No. 7,254,429 for the technology that is the core of the company’s first product, the Sentris-100™ glucose monitor... Sentris-100 is currently in clinical testing and the Company recently completed its first hypoglycemic “clamping study” that measured blood glucose fluctuations in volunteer subjects with Type 1 diabetes..... GlucoLight's Press Release -